8-K Announcements
6Material company update
Apr 29, 2026·SEC
Material company update
Jan 28, 2026·SEC
Material company update
Jan 12, 2026·SEC
Teva Pharmaceutical Industries Limited(TEVA)Earnings, Financials & Key Ratios
TEVA•NYSE
$36.34
$42.31B mkt cap·30.3× P/E·Price updated May 6, 2026
SectorHealthcareIndustrySpecialty & Generic PharmaSub-IndustryLarge-scale generic drug manufacturers
AboutTeva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.Show more
- Revenue$17.26B+4.3%
- EBITDA$3.16B+317.9%
- Net Income$1.41B+186.0%
- EPS (Diluted)1.20+182.8%
- Gross Margin51.79%+6.3%
- EBITDA Margin18.31%+300.6%
- Operating Margin12.5%+782.5%
- Net Margin8.17%+182.5%
- ROE20.68%+187.4%
- ROIC7.66%+867.7%
- Debt/Equity2.20-30.5%
- Interest Coverage2.34-34.8%
TEVA Key Insights
Teva Pharmaceutical Industries Limited (TEVA) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong Piotroski F-Score: 8/9
- ✓Momentum leader: RS Rating 86 (top 14%)
- ✓Trading near 52-week high
✗Weaknesses
- ✗High debt to equity ratio of 2.2x
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
TEVA Price & Volume
Teva Pharmaceutical Industries Limited (TEVA) stock price & volume — 10-year historical chart
Loading chart...
TEVA Growth Metrics
Teva Pharmaceutical Industries Limited (TEVA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-1.29%
5 Years0.71%
3 Years4.96%
TTM4.41%
Profit CAGR
10 Years-1.18%
5 Years-
3 Years-
TTM221.62%
EPS CAGR
10 Years-4.08%
5 Years-
3 Years-
TTM216.67%
Return on Capital
10 Years-3.03%
5 Years1.32%
3 Years2.77%
Last Year8.02%
TEVA Recent Earnings
Teva Pharmaceutical Industries Limited (TEVA) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 10/12 qtrs (83%)●Beat Revenue 10/12 qtrs (83%)
Q2 2026Latest
Apr 29, 2026EPS
$0.53
Est $0.50
+6.0%
Revenue
$4.0B
Est $3.8B
+5.1%
Q1 2026
Jan 28, 2026EPS
$0.96
Est $0.65
+47.7%
Revenue
$4.7B
Est $4.3B
+9.1%
Q4 2025
Nov 5, 2025EPS
$0.78
Est $0.68
+14.7%
Revenue
$4.5B
Est $4.5B
+0.6%
Q3 2025
Jul 30, 2025EPS
$0.66
Est $0.63
+4.8%
Revenue
$4.2B
Est $4.4B
-4.3%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 29, 2026 | $0.53vs $0.50+6.0% | $4.0Bvs $3.8B+5.1% |
| Q1 2026 | Jan 28, 2026 | $0.96vs $0.65+47.7% | $4.7Bvs $4.3B+9.1% |
| Q4 2025 | Nov 5, 2025 | $0.78vs $0.68+14.7% | $4.5Bvs $4.5B+0.6% |
| Q3 2025 | Jul 30, 2025 | $0.66vs $0.63+4.8% | $4.2Bvs $4.4B-4.3% |
Based on last 12 quarters of dataView full earnings history →
TEVA Peer Comparison
Teva Pharmaceutical Industries Limited (TEVA) competitors in Large-scale generic drug manufacturers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 VTRS | 18.37B | 15.95 | -5.32 | -2.98% | -24.58% | -23.89% | 0.98 | |
 PRGO | 1.69B | 12.26 | -1.19 | -2.75% | -43.5% | -50.65% | 1.35 | |
 AMRX | 4.28B | 13.62 | 61.91 | 8.05% | 2.39% | 7.47% | 0.13 | |
 SUPN | 2.96B | 51.45 | -75.66 | 8.63% | -3.74% | -2.73% | 0.04 | |
 LNTH | 5.61B | 86.15 | 25.26 | 0.5% | 15.15% | 20.58% | 0.00 | |
 PAHC | 2.38B | 58.64 | 49.28 | 27.37% | 6.29% | 30.81% | 2.67 | |
 MCK | 91.09B | 743.67 | 28.91 | 16.22% | 1.09% | |||
 CAH | 45.06B | 191.49 | 29.69 | -1.87% | 0.62% |
Compare TEVA vs Peers
Teva Pharmaceutical Industries Limited (TEVA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
TEVA Income Statement
Teva Pharmaceutical Industries Limited (TEVA) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 22.39B | 18.85B | 16.89B | 16.66B | 15.88B | 14.93B | 15.85B | 16.54B | 17.26B | 17.35B |
| Revenue Growth % | 2.2% | -15.77% | -10.43% | -1.35% | -4.69% | -6% | 6.16% | 4.41% | 4.31% | 4.41% |
| Cost of Goods Sold | 11.56B | 10.56B | 9.35B | 8.93B | 8.28B | 7.95B | 8.2B | 8.48B | 8.32B | 8.32B |
| COGS % of Revenue | 51.64% | 56% | 55.37% | 53.62% | 52.17% | 53.28% | 51.75% | 51.26% | 48.21% | - |
| Gross Profit | 10.82B▲ 0% | 8.3B▼ 23.4% | 7.54B▼ 9.2% | 7.73B▲ 2.5% | 7.59B▼ 1.7% | 6.97B▼ 8.2% | 7.64B▲ 9.6% | 8.06B▲ 5.5% | 8.94B▲ 10.9% | 9.03B▲ 0% |
| Gross Margin % | 48.36% | 44% | 44.63% | 46.38% | 47.83% | 46.72% | 48.25% | 48.74% | 51.79% | 52.08% |
| Gross Profit Growth % | -8.72% | -23.36% | -9.16% | 2.52% | -1.71% | -8.18% | 9.64% | 5.47% | 10.85% | - |
| Operating Expenses | 6.83B | 5.43B | 7.98B | 11.3B | 5.88B | 9.17B | 7.21B | 8.37B | 6.78B | 6.74B |
| OpEx % of Revenue | 30.53% | 28.78% | 47.25% | 67.82% | 37.02% | 61.44% | 45.52% | 50.57% | 39.29% | - |
| Selling, General & Admin | 4.99B | 4.21B | 3.81B | 3.67B | 3.53B | 3.44B | 3.5B | 3.7B | 3.97B | 4.05B |
| SG&A % of Revenue | 22.27% | 22.35% | 22.54% | 22.04% | 22.22% | 23.08% | 22.08% | 22.38% | 23.02% | - |
| Research & Development | 1.85B | 1.21B | 1.01B | 1.79B | 1.09B | 838M | 953M | 1.05B | 1.01B | 989M |
| R&D % of Revenue | 8.26% | 6.43% | 5.98% | 10.77% | 6.89% | 5.61% | 6.01% | 6.38% | 5.87% | - |
| Other Operating Expenses | 0 | 0 | 3.16B | 5.83B | 1.26B | 4.89B | 2.76B | 3.61B | 1.79B | 4M |
| Operating Income | -17.48B▲ 0% | -1.64B▲ 90.6% | -443M▲ 72.9% | -3.57B▼ 706.3% | 1.72B▲ 148.0% | -2.2B▼ 228.0% | 433M▲ 119.7% | -303M▼ 170.0% | 2.16B▲ 811.9% | 2.29B▲ 0% |
| Operating Margin % | -78.11% | -8.68% | -2.62% | -21.44% | 10.81% | -14.72% | 2.73% | -1.83% | 12.5% | 13.19% |
| Operating Income Growth % | -911.7% | 90.64% | 72.94% | -706.32% | 148.04% | -228.03% | 119.71% | -169.98% | 811.88% | - |
| EBITDA | -15.41B | 205M | 1.28B | -2.02B | 3.05B | -889M | 1.59B | 756M | 3.16B | 3.29B |
| EBITDA Margin % | -68.83% | 1.09% | 7.57% | -12.1% | 19.18% | -5.96% | 10.01% | 4.57% | 18.31% | 18.95% |
| EBITDA Growth % | -522.37% | 101.33% | 523.9% | -257.55% | 251.17% | -129.19% | 278.4% | -52.33% | 317.86% | 124.44% |
| D&A (Non-Cash Add-back) | 2.08B | 1.84B | 1.72B | 1.56B | 1.33B | 1.31B | 1.15B | 1.06B | 1B | 999M |
| EBIT | -17.59B | -1.66B | 2.72B | 3.06B | 3.08B | -2.23B | 405M | 3.37B | 2.14B | 2.27B |
| Net Interest Income | -872M | -881M | -916M | -731M | -891M | -930M | -961M | -941M | -916M | -905M |
| Interest Income | 3M | 0 | 41M | 24M | 0 | 0 | 68M | 0 | 0 | 0 |
| Interest Expense | 895M | 881M | 957M | 755M | 891M | 930M | 1.03B | 941M | 916M | 905M |
| Other Income/Expense | -895M | -959M | -280M | -359M | -1.05B | -945M | -1.05B | -980M | -919M | -910M |
| Pretax Income | -18.38B▲ 0% | -2.6B▲ 85.9% | -723M▲ 72.1% | -3.93B▼ 443.7% | 667M▲ 117.0% | -3.14B▼ 571.1% | -622M▲ 80.2% | -1.28B▼ 106.3% | 1.24B▲ 196.5% | 1.38B▲ 0% |
| Pretax Margin % | -82.1% | -13.77% | -4.28% | -23.6% | 4.2% | -21.05% | -3.93% | -7.76% | 7.17% | 7.95% |
| Income Tax | -1.93B | -195M | 278M | 168M | 211M | -643M | -7M | 676M | -180M | -187M |
| Effective Tax Rate % | 10.52% | 7.51% | -38.45% | -4.27% | 31.63% | 20.46% | 1.13% | -52.69% | -14.54% | -13.56% |
| Net Income | -16.27B▲ 0% | -2.15B▲ 86.8% | -999M▲ 53.5% | -3.99B▼ 299.4% | 417M▲ 110.5% | -2.45B▼ 686.6% | -559M▲ 77.1% | -1.64B▼ 193.2% | 1.41B▲ 186.0% | 1.56B▲ 0% |
| Net Margin % | -72.66% | -11.4% | -5.92% | -23.95% | 2.63% | -16.39% | -3.53% | -9.91% | 8.17% | 9.02% |
| Net Income Growth % | -5043.77% | 86.78% | 53.53% | -299.4% | 110.45% | -686.57% | 77.15% | -193.2% | 186.03% | 221.62% |
| Net Income (Continuing) | -16.45B | -2.47B | -1B | -4.1B | 456M | -2.5B | -615M | -1.96B | 1.42B | 1.57B |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 1.39B | 1.09B | 1.09B | 1.03B | 966M | 794M | 620M | 347M | 4M | 4M |
| EPS (Diluted) | -16.01▲ 0% | -2.11▲ 86.8% | -0.92▲ 56.4% | -3.64▼ 295.7% | 0.38▲ 110.4% | -2.20▼ 678.9% | -0.50▲ 77.3% | -1.45▼ 190.0% | 1.20▲ 182.8% | 1.33▲ 0% |
| EPS Growth % | -22971.43% | 86.82% | 56.4% | -295.65% | 110.44% | -678.95% | 77.27% | -190% | 182.76% | 216.67% |
| EPS (Basic) | -16.01 | -2.11 | -0.92 | -3.64 | 0.38 | -2.20 | -0.50 | -1.45 | 1.23 | - |
| Diluted Shares Outstanding | 1.02B | 1.02B | 1.09B | 1.09B | 1.11B | 1.11B | 1.12B | 1.13B | 1.17B | 1.18B |
| Basic Shares Outstanding | 1.02B | 1.02B | 1.09B | 1.09B | 1.1B | 1.11B | 1.12B | 1.13B | 1.15B | 1.16B |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
TEVA Balance Sheet
Teva Pharmaceutical Industries Limited (TEVA) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 15.38B | 13.79B | 13.46B | 13.01B | 12.57B | 12.05B | 12.48B | 12.55B | 13.95B | 13.71B |
| Cash & Short-Term Investments | 963M | 1.78B | 1.98B | 2.18B | 2.17B | 2.8B | 3.23B | 3.3B | 3.56B | 3.74B |
| Cash Only | 963M | 1.78B | 1.98B | 2.18B | 2.17B | 2.8B | 3.23B | 3.3B | 3.56B | 3.74B |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 7.13B | 5.82B | 5.68B | 4.58B | 4.53B | 3.7B | 3.41B | 3.06B | 3.71B | 3.39B |
| Days Sales Outstanding | 116.23 | 112.71 | 122.68 | 100.37 | 104.11 | 90.39 | 78.51 | 67.49 | 78.45 | 76.14 |
| Inventory | 4.92B | 4.73B | 4.42B | 4.4B | 3.82B | 3.83B | 4.02B | 3.01B | 3.18B | 3.18B |
| Days Inventory Outstanding | 155.47 | 163.56 | 172.61 | 179.91 | 168.22 | 175.94 | 178.98 | 129.41 | 139.46 | 144.55 |
| Other Current Assets | 1.27B | 560M | 521M | 899M | 986M | 559M | 575M | 2.18B | 2.38B | 2.33B |
| Total Non-Current Assets | 55.23B | 46.89B | 44.01B | 37.63B | 35.09B | 31.96B | 30.99B | 26.77B | 26.8B | 26.33B |
| Property, Plant & Equipment | 7.67B | 6.87B | 6.95B | 6.85B | 6.48B | 6.16B | 6.15B | 4.95B | 4.42B | 4.33B |
| Fixed Asset Turnover | 2.92x | 2.75x | 2.43x | 2.43x | 2.45x | 2.42x | 2.58x | 3.34x | 3.90x | 3.64x |
| Goodwill | 28.41B | 24.92B | 24.85B | 20.62B | 20.04B | 17.63B | 17.18B | 15.15B | 16B | 15.82B |
| Intangible Assets | 17.64B | 14.01B | 11.23B | 8.92B | 7.47B | 6.27B | 5.39B | 4.42B | 3.78B | 3.61B |
| Long-Term Investments | 25M | 58M | 0 | 0 | 0 | 0 | 8M | 0 | 0 | 0 |
| Other Non-Current Assets | 907M | 673M | 591M | 538M | 515M | 441M | 462M | 462M | 404.99M | 3.33B |
| Total Assets | 70.61B▲ 0% | 60.68B▼ 14.1% | 57.47B▼ 5.3% | 50.64B▼ 11.9% | 47.67B▼ 5.9% | 44.01B▼ 7.7% | 43.48B▼ 1.2% | 39.33B▼ 9.6% | 40.75B▲ 3.6% | 40.04B▲ 0% |
| Asset Turnover | 0.32x | 0.31x | 0.29x | 0.33x | 0.33x | 0.34x | 0.36x | 0.42x | 0.42x | 0.43x |
| Asset Growth % | -23.98% | -14.06% | -5.29% | -11.88% | -5.87% | -7.67% | -1.21% | -9.55% | 3.61% | 0.37% |
| Total Current Liabilities | 17.92B | 14.32B | 13.67B | 13.16B | 11.03B | 11.47B | 12.25B | 12.8B | 13.46B | 13.53B |
| Accounts Payable | 2.07B | 1.85B | 1.72B | 1.76B | 1.69B | 1.89B | 2.6B | 2.2B | 2.53B | 2.6B |
| Days Payables Outstanding | 65.33 | 64.06 | 67.06 | 71.75 | 74.29 | 86.61 | 115.82 | 94.81 | 111.03 | 109.5 |
| Short-Term Debt | 3.65B | 2.22B | 2.35B | 3.19B | 1.43B | 2.11B | 1.67B | 1.78B | 1.82B | 2.61B |
| Deferred Revenue (Current) | 11.44B | 9.45B | 0 | 7.29B | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 11.66B | 9.38B | 7.74B | 246M | 5.71B | 5.32B | 5.2B | 6.02B | 8.37B | 7.77B |
| Current Ratio | 0.86x | 0.96x | 0.98x | 0.99x | 1.14x | 1.05x | 1.02x | 0.98x | 1.04x | 1.04x |
| Quick Ratio | 0.58x | 0.63x | 0.66x | 0.65x | 0.79x | 0.72x | 0.69x | 0.75x | 0.80x | 0.80x |
| Cash Conversion Cycle | 206.37 | 212.2 | 228.23 | 208.53 | 198.05 | 179.71 | 141.67 | 102.09 | 106.87 | 111.2 |
| Total Non-Current Liabilities | 33.95B | 30.57B | 28.73B | 26.41B | 25.39B | 23.94B | 23.11B | 20.81B | 19.38B | 18.28B |
| Long-Term Debt | 28.83B | 26.7B | 24.56B | 22.73B | 21.62B | 19.1B | 18.16B | 16B | 15.27B | 14.02B |
| Capital Lease Obligations | 0 | 0 | 435M | 479M | 416M | 349M | 320M | 296M | 288M | 1.15B |
| Deferred Tax Liabilities | 3.28B | 2.14B | 1.1B | 964M | 784M | 548M | 606M | 483M | 296M | 1.41B |
| Other Non-Current Liabilities | 1.84B | 1.73B | 2.64B | 2.24B | 2.58B | 3.94B | 4.02B | 4.03B | 3.52B | 14.83B |
| Total Liabilities | 51.87B | 44.89B | 42.41B | 39.58B | 36.42B | 35.41B | 35.35B | 33.61B | 32.83B | 31.81B |
| Total Debt | 32.48B | 28.92B | 27.34B | 26.4B | 23.46B | 21.56B | 20.15B | 18.08B | 17.38B | 16.91B |
| Net Debt | 31.51B | 27.13B | 25.37B | 24.22B | 21.29B | 18.76B | 16.93B | 14.78B | 13.83B | 13.17B |
| Debt / Equity | 1.73x | 1.83x | 1.82x | 2.39x | 2.09x | 2.51x | 2.48x | 3.16x | 2.20x | 2.20x |
| Debt / EBITDA | - | 141.05x | 21.38x | - | 7.70x | - | 12.71x | 23.91x | 5.50x | 5.14x |
| Net Debt / EBITDA | - | 132.36x | 19.83x | - | 6.99x | - | 10.67x | 19.55x | 4.38x | 4.38x |
| Interest Coverage | -19.66x | -1.88x | 2.84x | 4.05x | 3.46x | -2.40x | 0.39x | 3.58x | 2.34x | 2.51x |
| Total Equity | 18.75B▲ 0% | 15.79B▼ 15.7% | 15.06B▼ 4.6% | 11.06B▼ 26.6% | 11.24B▲ 1.7% | 8.6B▼ 23.5% | 8.13B▼ 5.5% | 5.72B▼ 29.6% | 7.91B▲ 38.4% | 8.23B▲ 0% |
| Equity Growth % | -46.43% | -15.74% | -4.63% | -26.57% | 1.65% | -23.53% | -5.49% | -29.61% | 38.35% | 87.43% |
| Book Value per Share | 18.45 | 15.47 | 13.81 | 10.10 | 10.16 | 7.75 | 7.26 | 5.06 | 6.75 | 6.98 |
| Total Shareholders' Equity | 17.36B | 14.71B | 13.97B | 10.03B | 10.28B | 7.8B | 7.51B | 5.37B | 7.91B | 8.23B |
| Common Stock | 54M | 56M | 56M | 57M | 57M | 57M | 57M | 58M | 58M | -4.07B |
| Retained Earnings | -3.8B | -5.96B | -6.96B | -10.95B | -10.53B | -12.97B | -13.53B | -15.17B | -13.76B | -13.39B |
| Treasury Stock | -4.15B | -4.14B | -4.13B | -4.13B | -4.13B | -4.13B | -4.13B | -4.13B | -4.13B | 0 |
| Accumulated OCI | -1.85B | -2.46B | -2.31B | -2.4B | -2.68B | -2.84B | -2.7B | -3.15B | -2.39B | -2.51B |
| Minority Interest | 1.39B | 1.09B | 1.09B | 1.03B | 966M | 794M | 620M | 347M | 4M | 4M |
TEVA Cash Flow Statement
Teva Pharmaceutical Industries Limited (TEVA) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | 3.51B | 2.45B | 538M | 1.22B | 798M | 1.59B | 1.37B | 1.25B | 1.65B | 1.65B |
| Operating CF Margin % | 15.67% | 12.97% | 3.19% | 7.3% | 5.03% | 10.65% | 8.63% | 7.54% | 9.56% | - |
| Operating CF Growth % | -32.88% | -30.25% | -78% | 126.02% | -34.38% | 99.25% | -13.96% | -8.85% | 32.24% | 236.93% |
| Net Income | -16.45B | -2.47B | 76M | -4.1B | 456M | -2.41B | -615M | -1.96B | 1.42B | 1.56B |
| Depreciation & Amortization | 2.11B | 1.84B | 416M | 1.56B | 1.33B | 1.31B | 1.15B | 1.06B | 1B | 999M |
| Stock-Based Compensation | 133M | 155M | 20M | 129M | 119M | 124M | 121M | 123M | 157M | 166M |
| Deferred Taxes | -2.33B | -837M | -333M | -696M | -120M | -1.06B | -317M | -634M | -671M | -699M |
| Other Non-Cash Items | 20.41B | 5.58B | 471M | 6.51B | 714M | 2.37B | 1.1B | 3.09B | 1.11B | 349M |
| Working Capital Changes | -363M | -1.82B | -112M | -2.19B | -1.7B | 1.26B | -72M | -435M | -1.37B | -668M |
| Change in Receivables | 514M | 88M | -394M | -293M | -574M | 334M | 12M | 245M | -173M | 354M |
| Change in Inventory | 266M | 26M | 271M | 41M | 380M | -163M | -147M | 166M | 152M | 0 |
| Change in Payables | -1.8B | -500M | 643M | -463M | 764M | 1.91B | 1.59B | 258M | -15M | 0 |
| Cash from Investing | 2.16B | 1.87B | 430M | 863M | 1.52B | 656M | 968M | 792M | 737M | 765M |
| Capital Expenditures | -874M | -651M | -119M | -578M | -562M | -548M | -526M | -498M | -501M | -542M |
| CapEx % of Revenue | 3.9% | 3.45% | 0.7% | 3.47% | 3.54% | 3.67% | 3.32% | 3.01% | 2.9% | - |
| Acquisitions | 43M | 1.74B | -343M | 67M | 1.96B | 61M | 68M | 28M | 34M | 17M |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 3.19B | 11M | 552M | 1.42B | 1M | 1.14B | 1.47B | 1.29B | 1.22B | 1.29B |
| Cash from Financing | -5.75B | -3.35B | -241M | -1.89B | -2.17B | -1.49B | -1.91B | -1.79B | -2.15B | -394M |
| Debt Issued (Net) | -4.48B | -3.27B | -1.86B | -1.88B | -2.17B | -1.37B | -1.7B | -1.64B | -1.81B | -493.23M |
| Equity Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | -1.16B | -22M | -52M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | -112M | -57M | 1.67B | -5M | -6M | -118M | -212M | -150M | -337M | 99.23M |
| Net Change in Cash | -25M▲ 0% | 819M▲ 3376.0% | 734M▼ 10.4% | 202M▼ 72.5% | 21M▼ 89.6% | 636M▲ 2928.6% | 393M▼ 38.2% | 73M▼ 81.4% | 256M▲ 250.7% | 2.04B▲ 0% |
| Free Cash Flow | 2.63B▲ 0% | 1.79B▼ 31.8% | 419M▼ 76.7% | 638M▲ 52.3% | 236M▼ 63.0% | 1.04B▲ 341.5% | 842M▼ 19.2% | 749M▼ 11.0% | 1.15B▲ 53.3% | 1.17B▲ 0% |
| FCF Margin % | 11.76% | 9.52% | 2.48% | 3.83% | 1.49% | 6.98% | 5.31% | 4.53% | 6.65% | 6.76% |
| FCF Growth % | -39.11% | -31.83% | -76.66% | 52.27% | -63.01% | 341.53% | -19.19% | -11.05% | 53.27% | 53.2% |
| FCF per Share | 2.59 | 1.76 | 0.38 | 0.58 | 0.21 | 0.94 | 0.75 | 0.66 | 0.98 | 0.98 |
| FCF Conversion (FCF/Net Income) | -0.22x | -1.14x | -0.54x | -0.30x | 1.91x | -0.65x | -2.45x | -0.76x | 1.17x | 0.75x |
| Interest Paid | 795M | 815M | 840M | 846M | 913M | 948M | 1.08B | 1B | 0 | 0 |
| Taxes Paid | 106M | 420M | 552M | 709M | 495M | 543M | 298M | 471M | 0 | 0 |
TEVA Key Ratios
Teva Pharmaceutical Industries Limited (TEVA) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -60.53% | -12.45% | -6.48% | -30.55% | 3.74% | -24.65% | -6.69% | -23.67% | 20.68% | 20.69% |
| Return on Invested Capital (ROIC) | -21.84% | -2.64% | -0.8% | -7.08% | 3.8% | -5.5% | 1.24% | -1% | 7.66% | 7.66% |
| Gross Margin | 48.36% | 44% | 44.63% | 46.38% | 47.83% | 46.72% | 48.25% | 48.74% | 51.79% | 52.08% |
| Net Margin | -72.66% | -11.4% | -5.92% | -23.95% | 2.63% | -16.39% | -3.53% | -9.91% | 8.17% | 9.02% |
| Debt / Equity | 1.73x | 1.83x | 1.82x | 2.39x | 2.09x | 2.51x | 2.48x | 3.16x | 2.20x | 2.20x |
| Interest Coverage | -19.66x | -1.88x | 2.84x | 4.05x | 3.46x | -2.40x | 0.39x | 3.58x | 2.34x | 2.51x |
| FCF Conversion | -0.22x | -1.14x | -0.54x | -0.30x | 1.91x | -0.65x | -2.45x | -0.76x | 1.17x | 0.75x |
| Revenue Growth | 2.2% | -15.77% | -10.43% | -1.35% | -4.69% | -6% | 6.16% | 4.41% | 4.31% | 4.41% |
TEVA SEC Filings & Documents
Teva Pharmaceutical Industries Limited (TEVA) SEC filings — annual & quarterly reports (10-K, 10-Q)
TEVA Frequently Asked Questions
Teva Pharmaceutical Industries Limited (TEVA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Teva Pharmaceutical Industries Limited (TEVA) reported $17.35B in revenue for fiscal year 2025. This represents a 1719% increase from $953.8M in 1996.
Teva Pharmaceutical Industries Limited (TEVA) grew revenue by 4.3% over the past year. Growth has been modest.
Yes, Teva Pharmaceutical Industries Limited (TEVA) is profitable, generating $1.56B in net income for fiscal year 2025 (8.2% net margin).
Dividend & Returns
Teva Pharmaceutical Industries Limited (TEVA) has a return on equity (ROE) of 20.7%. This is excellent, indicating efficient use of shareholder capital.
Teva Pharmaceutical Industries Limited (TEVA) generated $1.17B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
Explore More TEVA
Teva Pharmaceutical Industries Limited (TEVA) financial analysis — history, returns, DCA and operating performance tools
Full TEVA Stock Analysis
Analyst verdict, bull/bear case, risk factors and peer comparison
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates